University of Leicester spin-out technology hailed as ‘most commercially viable’

Posted by ap507 at Sep 16, 2015 11:35 AM |
MIP Diagnostics recognised at Europe’s flagship Drug Discovery conference

Issued by the University of Leicester Press Office on 16 September 2015

Contact to request images.

A technology developed at the University of Leicester, and the prime focus of Leicester spin-out company MIP Diagnostics, has been recognised as ‘most commercially viable’ at Europe’s flagship Drug Discovery event.

The annual ELRIG Drug Discovery conference, held at the Telford International Centre in September, is the largest Drug Discovery conference in Europe and featured a ‘Dragons’ Den’ competition. The coveted trophy is awarded to the product or service considered to be the most commercially viable and with the best prospects for generating significant revenues.

The ‘Dragons’ -  Alan Fletcher, VP Reagents & New Markets at PerkinElmer; Ann Kramer, CEO of The Electrospinning Company; and  Gary Allenby, CSO at Aurelia Bioscience – believed that the nanoMIP technology was "potentially disruptive" in the affinity reagent field due to the speed of delivery and robustness of the nanoMIPs (molecular imprinted polymers), sometime called 'plastic antibodies'.

The MIP technology is the result of extensive research led by Sergey Piletsky, Professor in Bioanalytical Chemistry at University of Leicester.

Commenting on the accolade, Dr Adrian Kinkaid, CEO of MIP Diagnostics Ltd said: “This is a great endorsement of this cutting-edge technology. The Dragons clearly recognised the potential of the product and its possible application in a variety of sectors, from drug discovery applications to monitoring food contaminants or protecting the population from the growing danger of so-called ‘legal highs’.”

Dr Kinkaid was recently appointed CEO of the company following an investment of £182,000 by Mercia Fund Management.


Notes to Editors:

About MIP Diagnostics

MIP Diagnostics Ltd was founded in 2015 as a spin-out from the University of Leicester by several leading experts in the field, including Leicester academic Professor Sergey Piletsky. The company aims to commercialise various forms of Molecularly Imprinted Polymers (MIPs), sometimes called ‘plastic antibodies’. Its proprietary technology includes a novel method to make nanoMIPs which circumvents the drawbacks of traditional MIP manufacturing methods. NanoMIPS are, as the name suggests, nanostructured polymer particles typically containing a single binding site for their target. Whilst MIPs are exceptionally robust polymers [plastics], nanoMIPS are sufficiently small to be essentially soluble. MIPs have successfully been created and deployed against all major target classes including peptides, proteins and other macromolecular structures, as well as smaller chemical entities such as drugs, their metabolites and commonly used biochemical species such as enzyme cofactors.

About Mercia Fund Management

Mercia Fund Management is a technology investor focusing on start-ups and spin-outs in the Midlands, North and Scotland.

Share this page: